Showing 21-30 of 216 results for "".
“No Drug is 100 Percent.”
https://practicaldermatology.com/conferences/maui-derm-2024/no-drug-is-100-percent/20242/Jason Hawkes, MD and Chief Medical Editor Neal Bhatia, MD discuss how the current array of options for patients of chronic spontaneous urticaria (CSU) expand treatment options for hives beyond antihistamines.Managing Office Politics
https://practicaldermatology.com/topics/practice-management/managing-office-politics/19101/Neal Bhatia, MD, Co-Chief Medical Editor of Practical Dermatology® magazine, shares pearls for successfully understanding and navigating the scope of office politics and relationships. DermTube's coverage of the AAD's 2014 Summer Meeting is not endorsed by or affiliated with the American Academy ofThe Landscape for Vitiligo: An Interview with Larry Green, MD
https://practicaldermatology.com/topics/pigmentary-disorders/the-landscape-for-vitiligo-an-interview-with-larry-green-md/24209/Practical Dermatology® Chief Medical Editor Neal Bhatia, MD, FAAD, talked with Larry Green, MD, a board-certified dermatologist in private practice in Rockville, Maryland, about the latest in vitiligo treatment and what practitioners can tell their patients about recent advances in treatment for thiBurnout: Is Personal Happiness the Answer?
https://practicaldermatology.com/series/the-practical-dermatology-podcast/burnout-is-personal-happiness-the-answer/18191/Physician burnout remains a conversation, and the pandemic dramatically changed the landscape for dermatologists—for better and for worse. Omaha, NE-based Joel Schlessinger, MD, who serves as Chief Cosmetic Surgery Editor of Practical Dermatology® speaks with Las Vegas-based dermatologist H.L. GreenActive Vitiligo: What to Look for
https://practicaldermatology.com/series/updates-vitiligo/active-vitiligo-what-to-look-for/24156/John E. Harris, MD, founding director of the Autoimmune Therapeutics Institute at the University of Massachusetts Chan Medical School, talks with Practical Dermatology Chief Medical Editor Neal Bhatia, MD, about the clinical signs of active vitiligo.Anti-Semitism and Dermatologists
https://practicaldermatology.com/columns/editors-message/anti-semitism-and-dermatologists/23988/(A Personal Narrative from the Editor)The Landscape of Vitiligo Treatment
https://practicaldermatology.com/series/updates-vitiligo/the-landscape-of-vitiligo-treatment/24467/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, talks with Lawrence Green, MD, a dermatologist practicing in Rockville, MD, about the landscape of treatments for patients with vitiligo and new therapies that may be coming from ongoing clinical trials.Embracing Photodynamic Therapy (PDT) in Your Practice
https://practicaldermatology.com/series/pdt-in-practice/embracing-photodynamic-therapy-pdt-in-your-practice/20209/Dr. Neal Bhatia, Chief Medical Editor of Practical Dermatology, provides updates in photodynamic therapy (PDT) and how to incorporate its techniques and technologies into everyday practice. Dr. Bhatia also provides some practical advice on using the therapy and on protecting yourself and your patienHilary Baldwin, MD: Perspective on the FDA Citizen's Petition for Acne Products with Benzoyl Peroxide (BPO)
https://practicaldermatology.com/topics/acne-rosacea/hilary-baldwin-md-perspective-fda-citizens-petition-acne-products-benzoyl-peroxide-bpo/24171/Neal Bhatia, MD, chief medical editor of Practical Dermatology® talks to Hilary E. Baldwin, MD about a new report from an independent laboratory that finds benzene can form at unacceptably high levels in both over-the-counter and prescription medications that contain benzoyl peroxide.Valeant Business Update; Melanoma Drugs Approved
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-valeant-business-update-melanoma-drugs-approved/18679/In this edition of DermWireTV from the editors of Practical Dermatology® magazine and DermWire.com, we take a look at Valeant's warning of disruption of dermatology business following its break from specialty pharmacy Philidor. Plus, an update on Melanoma Therapeutics, including approvals of Imlygic